Market Access News | pharmaphorum

News

FDA panel backs Ardelyx CKD drug, despite agency concerns

While the FDA seems to remain sceptical about the clinical benefits of Ardelyx's chronic kidney disease (CKD) therapy Xphozah – having

News

teva_uk_house_of_lords_committee_paul_williams_evidence3

Teva says medicines access at risk in Northern Ireland

The North Ireland Protocol has been a source of tension between the UK and EU since it came into force at the start of 2021 – and, according to one pharma company, the end of the so-called

News

GSK, J&J, and AZ head this year's access to medicines rankin...

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK re

News

NICE rejects five COVID drugs and backs three on price, effi...

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer's Paxlovid, Roche's RoActemra, and Eli Lilly's Olumiant – but turned down another five

News

Dupixent nears EU approval for rare skin disease prurigo nod...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease.

News

AZ claims another Imjudo approval, in big first-line NSCLC m...

Just a couple of weeks after finally getting its first FDA approval for CTLA4 inhibitor Imjudo for advanced liver cancer, AstraZeneca has picked up another – and in a much larger patient po

FDA panel backs Ardelyx CKD drug, despite agency concerns

Teva says medicines access at risk in Northern Ireland

GSK, J&J, and AZ head this year's access to medicines rankin...

NICE rejects five COVID drugs and backs three on price, effi...

Dupixent nears EU approval for rare skin disease prurigo nod...

AZ claims another Imjudo approval, in big first-line NSCLC m...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks